Mechanism and therapeutic potential of targeting cGAS-STING signaling in neurological disorders.
Journal Information
Full Title: Mol Neurodegener
Abbreviation: Mol Neurodegener
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Subject Category: Molecular Biology
Available in Europe PMC: Yes
Available in PMC: Yes
PDF Available: No
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Declarations Competing interestsL.G. is founder and consultant of Aeton Therapeutics, Inc. S.C.S. is an equity holder and a consultant of Aeton Therapeutics, Inc. Competing interests L.G. is founder and consultant of Aeton Therapeutics, Inc. S.C.S. is an equity holder and a consultant of Aeton Therapeutics, Inc."
"Funding NIH (R01AG072758 to L.G., R01AG054214 to L.G., R01AG074541 to L.G. and S.C.S), Tau Consortium and JPB Foundation (to L.G.), CureAD fund (to L.G. and S.C.S.), Daedalus fund (L.G. and S.C.S.), BrightFocus Foundation Postdoctoral Fellowship in Alzheimer’s Disease Research A20201312F (to S.A.) and JumpStart Research Career Development Program (to S.A.)."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025